Anti-CD19 chimeric antigen receptor T cell therapy - Beijing Sanwater Biological Technology

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Beijing Sanwater Biological Technology

Alternative Names: CART-19 therapy - Beijing Sanwater Biological Technology

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator Beijing Sanwater Biological Technology
  • Class T lymphocyte cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia

Most Recent Events

  • 01 May 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater) in China (IV) (NCT02810223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top